EMA invites comments on consultation process for drug/device products

This article was originally published in Clinica

10 Nov 2010
News

Executive Summary

The European Medicines Agency has launched for comment a 16-page draft guidance on how notified bodies consult the agency on products that combine devices with "an ancillary medicinal substance or an ancillary human blood derivate".

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT096029

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT096029

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

EMA invites comments on consultation process for drug/device products

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert